<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pregnancy Childbirth</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pregnancy Childbirth</journal-id><journal-title-group><journal-title>BMC Pregnancy and Childbirth</journal-title></journal-title-group><issn pub-type="epub">1471-2393</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25884778</article-id><article-id pub-id-type="pmc">4391332</article-id><article-id pub-id-type="publisher-id">488</article-id><article-id pub-id-type="doi">10.1186/s12884-015-0488-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Koren</surname><given-names>Gideon</given-names></name><address><email>gkoren@sickkids.ca</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Shannon</given-names></name><address><email>shclark@utmb.edu</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Hankins</surname><given-names>Gary D V</given-names></name><address><email>ghankins@utmb.edu</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Caritis</surname><given-names>Steve N</given-names></name><address><email>carisn@mail.magee.edu</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Umans</surname><given-names>Jason G</given-names></name><address><email>Jason.umans@gmail.com</email></address><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Miodovnik</surname><given-names>Menachem</given-names></name><address><email>mmiodovnik@gmail.com</email></address><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Mattison</surname><given-names>Donald R</given-names></name><address><email>Donald.mattison@gmail.com</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Matok</surname><given-names>Ilan</given-names></name><address><email>ilanmatok@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>From the Motherisk Program, Hospital for Sick Children and University of Toronto, Toronto, Canada </aff><aff id="Aff2"><label/>Department of Obstetrics and Gynecology, University of Texas, Medical Branch Galveston, Galveston, TX USA </aff><aff id="Aff3"><label/>Department of Obstetrics and Gynecology, University of Pittsburgh, Medical Center, Pittsburgh, PA USA </aff><aff id="Aff4"><label/>Medstar Health Research Institute, Hyattsville MD, and the Georgetown- Howard Universities Center for Clinical and Translational Science, Washington, DC USA </aff><aff id="Aff5"><label/>The Obstetric Pharmacology Research Unit Network, Eunice Kennedy Shriver, National Institute of Child and Human Development, Bethesda, MD USA </aff><aff id="Aff6"><label/>Division of Clinical Pharmacy, Institute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel </aff><aff id="Aff7"><label/>Division of Clinical Pharmacology/Toxicology, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8 Canada </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>59</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Koren et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis&#x000ae;) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis&#x000ae; as compared to placebo.</p></sec><sec><title>Methods</title><p>We randomized women suffering from NVP to receive Diclegis&#x000ae; (n&#x02009;=&#x02009;131) or placebo (n&#x02009;=&#x02009;125) for 14&#x000a0;days at doses ranging from 2&#x02013;4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing.</p></sec><sec><title>Results</title><p>Doxylamine succinate 10&#x000a0;mg and pyridoxine hydrochloride 10&#x000a0;mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement.</p></sec><sec><title>Conclusions</title><p>Doxylamine succinate&#x02013;pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy.</p></sec><sec><title>Trial Registration</title><p>Clinical Trial Registration No: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00614445?term=NCT00614445&#x00026;rank=1">NCT00614445</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Doxylamine</kwd><kwd>Pyridoxine</kwd><kwd>Nausea and vomiting of pregnancy</kwd><kwd>Diclegis</kwd><kwd>Safety</kwd><kwd>Toxicology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Nausea and vomiting of pregnancy (NVP) affect up to 80% of expecting mothers, and while lifestyle changes may be helpful, many women need medications to control their symptoms [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>The delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Bendectin&#x000ae;) was commonly used for NVP and was the only drug approved by the FDA until the manufacturer&#x02019;s voluntary removal of it from the market in 1983 [<xref ref-type="bibr" rid="CR3">3</xref>]. In 1983 [<xref ref-type="bibr" rid="CR4">4</xref>] and 1999 [<xref ref-type="bibr" rid="CR5">5</xref>], the FDA determined that this drug combination was not withdrawn from sale for reasons of safety and effectiveness. In fact, its removal from the American market was temporally associated with a 2-fold increase in rates of hospitalization of pregnant women for the most severe form of NVP, hyperemesis gravidarum [<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>]. Over the last 3 decades a large body of evidence corroborated the fetal safety of this drug combination [<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>The rationale for the delayed-release characteristics of this combination is to allow women to take it before bedtime, when symptoms of NVP tend to be minimal, in order to counteract the increased symptoms more commonly experienced in the morning hours [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref>]. In April 2013, the FDA approved the sale of Diclegis&#x000ae;, an identical combination to the original Bendectin&#x000ae; and its Canadian equivalent Diclectin&#x000ae;, after a randomized blinded placebo- controlled trial [<xref ref-type="bibr" rid="CR12">12</xref>]. The fetal safety of this medication has been proven by numerous studies. However, since it is the only FDA-approved medication for NVP, it is likely to be used by a large number of pregnant women, confirming maternal safety is an important public health question.</p><p>The objective of this study was to evaluate the maternal safety of Diclegis&#x000ae; in treating NVP compared to placebo.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><p>This is a secondary analysis of a double-blind, randomized, multicenter, placebo-controlled study of the delayed-release combination of doxylamine succinate (10&#x000a0;mg) and pyridoxine hydrochloride (10&#x000a0;mg) (Diclegis&#x000ae;) in the treatment of NVP [<xref ref-type="bibr" rid="CR12">12</xref>]. The study was approved by the IRB of the University of Texas, Galveston, University of Pittsburg and Georgetown University. The subjects were pregnant, at least 18&#x000a0;years of age, in the gestational age range of 7&#x02013;14 weeks, suffering from NVP, had a PUQE score&#x02009;&#x02265;&#x02009;6) [<xref ref-type="bibr" rid="CR13">13</xref>-<xref ref-type="bibr" rid="CR15">15</xref>], and had not responded to conservative management consisting of dietary/lifestyle advice [<xref ref-type="bibr" rid="CR16">16</xref>]. Women treated by other antiemetics, suffering from chronic medical conditions, or those who could not communicate in either English or Spanish, were excluded. After physical examination and laboratory tests (hemoglobin and blood count, liver function tests, electrolytes, amylase), and after confirming <italic>in utero</italic> singleton pregnancies by ultrasound, women were randomized, using a computerized program, to receive Diclegis&#x000ae; (doxylamine succinate 10&#x000a0;mg and pyridoxine hydrochloride 10&#x000a0;mg) or placebo of similar look. Two tablets of study drug (Diclegis&#x000ae; or placebo) were administered at bedtime on Day 1. If symptoms of nausea and vomiting persisted into the afternoon hours of Day 2 (<italic>i.e.,</italic> PUQE Score above 3), the subject was directed to take her usual dose of 2 tablets at bedtime and an additional tablet the next morning on Day 3. Based upon assessment in the clinic on Day 4 (+/&#x02212;1&#x000a0;day), the subject might have been directed to take an additional 4th tablet mid-afternoon to control evening symptoms. The minimum assigned study medication was 2 tablets daily at bedtime, increasing when indicated to the maximal dosage of 4 tablets per day according to the timing, duration, severity, and frequency of the symptoms experienced by the subject. The study had a 15&#x000a0;day period consisting of 14 dosing days. Telephone contact was made on day 2, 6, 12, and 14 in order to assess subject diary information, adverse events (AEs), concomitant medications, and compliance with the study medication. Patients returned to the clinic in the morning prior to their morning dose on Day 4 (+/&#x02212; 1&#x000a0;day), Day 8 (+/&#x02212; 1&#x000a0;day), and on Day 15 (+/&#x02212; 1&#x000a0;day; end of study visit) to collect diary report and complete all study related data.</p><p>Subjects completed the Pregnancy-Unique Quantification of Emesis (PUQE) score and the study diary (once daily every morning prior to study dose at approximately the same time each day). They also completed the Global Assessment of Well Being scale of the PUQE on Days 1, 8, and 14 at the same time the PUQE score was completed.</p><p>Adverse events and concomitant medications were recorded at all visits and follow-up phone calls. An additional follow-up phone call was conducted 30&#x000a0;days after last dosing to capture serious adverse events for patients completing the treatment period or early termination.</p><p>The results of the effectiveness of the drug in this trial have been previously published [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>The frequency and severity of all AEs were tabulated by treatment group, system organ class, preferred term severity, and relationship to study drug. In addition, laboratory tests were conducted on Days 1 and15 (&#x000b1;1&#x000a0;day).</p><p>Adverse events (AEs) experienced by the subjects that occurred on or after Day 1 (after the patient signed the informed consent form) through Day 15, were compared between groups using Pearson&#x02019;s Chi-square test or Fisher&#x02019;s exact test if more appropriate. The available sample size has 80% power to show a doubling in CNS depression with alpha of 5%.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>Two hundred and eighty-three pregnant women experiencing NVP were enrolled and randomized. After written informed consent nine subjects randomized to Diclegis&#x000ae; (6.4%) and 18 randomized to Placebo (12.9%) withdrew consent. Therefore, 131 women in Diclegis&#x000ae; treated group and 125 receiving placebo were analyzed. The two groups did not differ in any demographic or medical characteristics (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Comparison of demographic and medical characteristics of the two study groups in the ITT population</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Diclegis (n-131)</bold>
</th><th>
<bold>Placebo (n&#x02009;=&#x02009;125)</bold>
</th><th>
<bold><italic>P</italic></bold>
<bold>-value</bold>
</th></tr></thead><tbody><tr valign="top"><td>
<bold>Ethnicity:</bold>
</td><td/><td/><td>0.48</td></tr><tr valign="top"><td>
<bold>Hispanic or Latino</bold>
</td><td>53 (40.5%)</td><td>56 (44.8%)</td><td/></tr><tr valign="top"><td>
<bold>Not Hispanic or Latino</bold>
</td><td>78 (59.5%)</td><td>69 (55.2%)</td><td/></tr><tr valign="top"><td>Race:</td><td/><td/><td>0.59</td></tr><tr valign="top"><td>Asian</td><td>2 (1.5%)</td><td>1 (0.8%)</td><td/></tr><tr valign="top"><td>Black or African American</td><td>49 (37.4%)</td><td>48 (38.4%)</td><td/></tr><tr valign="top"><td>White or Caucasian</td><td>80 (61.1%)</td><td>73 (58.4%)</td><td/></tr><tr valign="top"><td>Unknown</td><td/><td>3 (2.4%)</td><td/></tr><tr valign="top"><td>Previous Pregnancy</td><td>101 (77.1%)</td><td>94 (75.2%)</td><td>0.64</td></tr><tr valign="top"><td>Smoking during pregnancy</td><td>17 (13.0%)</td><td>16 (12.8%)</td><td>0.97</td></tr><tr valign="top"><td>Maternal Age (yr)</td><td>25.9&#x02009;&#x000b1;&#x02009;6</td><td>25.0&#x02009;&#x000b1;&#x02009;5.7</td><td>0.23</td></tr><tr valign="top"><td>Weight (kg)</td><td>74.10&#x02009;&#x000b1;&#x02009;22.30</td><td>75.91&#x02009;&#x000b1;&#x02009;22.19</td><td>0.50</td></tr><tr valign="top"><td>(lbs)</td><td>163.35&#x02009;&#x000b1;&#x02009;49.17</td><td>167.34&#x02009;&#x000b1;&#x02009;48.91</td><td>0.50</td></tr><tr valign="top"><td>BMI (kg/m<sup>2</sup>):</td><td/><td/><td>0.42</td></tr><tr valign="top"><td>Underweight</td><td>5 (3.8%)</td><td>4 (3.2%)</td><td/></tr><tr valign="top"><td>Normal</td><td>39 (29.8%)</td><td>38 (30.4%)</td><td/></tr><tr valign="top"><td>Overweight</td><td>31 (23.7%)</td><td>40 (32.0%)</td><td/></tr><tr valign="top"><td>Obese</td><td>55 (42.0%)</td><td>42 (33.6%)</td><td/></tr><tr valign="top"><td>BMI (kg/m<sup>2</sup>)</td><td/><td/><td>0.95</td></tr><tr valign="top"><td>Mean&#x02009;&#x000b1;&#x02009;SD</td><td>28.77&#x02009;&#x000b1;&#x02009;7.60</td><td>29.67&#x02009;&#x000b1;&#x02009;11.20</td><td/></tr><tr valign="top"><td>Median</td><td>27.97</td><td>26.83</td><td/></tr><tr valign="top"><td>Gestational age at start of NVP (weeks)</td><td/><td/><td>0.90</td></tr><tr valign="top"><td>Mean&#x02009;&#x000b1;&#x02009;SD</td><td>5.5&#x02009;&#x000b1;&#x02009;1.8</td><td>5.4&#x02009;&#x000b1;&#x02009;1.7</td><td/></tr><tr valign="top"><td>Gestational age at enrollment (weeks)</td><td/><td/><td>0.75</td></tr><tr valign="top"><td>Mean&#x02009;&#x000b1;&#x02009;SD</td><td>9.3&#x02009;&#x000b1;&#x02009;2.0</td><td>9.3&#x02009;&#x000b1;&#x02009;1.8</td><td/></tr><tr valign="top"><td>PUQE score at Enrollment</td><td/><td/><td>0.44</td></tr><tr valign="top"><td>Mean&#x02009;&#x000b1;&#x02009;SD</td><td>9.0&#x02009;&#x000b1;&#x02009;2.1</td><td>8.8&#x02009;&#x000b1;&#x02009;2.1</td><td/></tr><tr valign="top"><td>Median</td><td>9.0</td><td>8.0</td><td/></tr><tr valign="top"><td>Global Assessment of Well Being</td><td/><td/><td/></tr><tr valign="top"><td>Mean&#x02009;&#x000b1;&#x02009;SD</td><td>5.0&#x02009;&#x000b1;&#x02009;2.3</td><td>5.4&#x02009;&#x000b1;&#x02009;2.2</td><td/></tr><tr valign="top"><td>Median</td><td>5.0</td><td>5.0</td><td/></tr></tbody></table></table-wrap></p><p>The use of Diclegis&#x000ae; was not associated with an overall increased rate of adverse effects as compared to the Placebo group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Of particular interest, the active drug was not associated with increased rates of symptoms known to be associated with antihistamines, such as sedation, symptoms of CNS depression and gastrointestinal or anticholinergic symptoms (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Diclegis&#x000ae; was also not associated with either more frequently occurring adverse events (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), or with an increase in Treatment Emergent Adverse Events (TEAEs) -as defined by the investigators, blinded to study drug allocation (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). TEAEs were defined as any adverse event that emerged after the treatment (either the drug or the placebo) were commenced.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Overall summary of tolerability/adverse events for ITT-S subjects</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Treatment group</bold>
</th></tr><tr valign="top"><th/><th>
<bold>Diclegis (N&#x02009;=&#x02009;131)</bold>
</th><th>
<bold>Placebo (N&#x02009;=&#x02009;127)</bold>
</th><th>
<bold>P-value</bold>
<sup><bold>1</bold></sup>
</th></tr><tr valign="top"><th>
<bold>Measure of tolerability</bold>
</th><th/><th/><th/></tr></thead><tbody><tr valign="top"><td>Number of Subjects with at least one treatment-emergent AE</td><td>74 (56.5%)</td><td>65 (51.2%)</td><td>0.393</td></tr><tr valign="top"><td>Number of Subjects with a serious treatment-emergent AE</td><td>4 (3.1%)</td><td>4 (3.1%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Number of Subjects with at least one Related AE</td><td>40 (30.5%)</td><td>32 (25.2%)</td><td>0.339</td></tr><tr valign="top"><td>Number of Subjects discontinuing study drug due to AE</td><td>6 (4.6%)</td><td>4 (3.1%)</td><td>0.749<sup>2</sup>
</td></tr><tr valign="top"><td>Number of deaths</td><td>0</td><td>0</td><td>_</td></tr><tr valign="top"><td>Overall treatment0emergent AEs</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least one Mild AE</td><td>62 (47.3%)</td><td>59 (46.5%)</td><td>0.221</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least one Moderate AE</td><td>5 (3.8%)</td><td>1 (0.8%)</td><td>0.215<sup>2</sup>
</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least one Severe AE</td><td>7 (5.3%)</td><td>5 (3.9%)</td><td>0.711</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with Unrelated AE</td><td>34 (26.0%)</td><td>33 (26.0%)</td><td>0.570</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least one Possibly Related AE</td><td>24 (18.3%)</td><td>23 (18.1%)</td><td>0.714</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least one Probably Related AE</td><td>13 (9.9%)</td><td>8 (6.3%)</td><td>0.388</td></tr><tr valign="top"><td>&#x02003;Number of Subjects with at least on Definitely Related AE</td><td>3 (2.3%</td><td>1 (0.8%)</td><td>0.623<sup>2</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>1</sup>The p-value for comparing Treatment groups uses Chi-square test method.</p><p>
<sup>2</sup>P-value is calculated using Fisher&#x02019;s exact test method.</p><p>Related category includes Possible, Probable, and Definite relationships. Unrelated category includes unlikely and not related.</p><p>Subjects reporting more than one AE will only be counted under the strongest relationship and/or severity.</p><p>Mild: asymptomatic or mild symptoms, intervention not needed; Moderate: minimal, local or non invasive intervention indicated; Severe: medically significant.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Treatment Emergent Adverse Events (TEAEs) in the study for ITT-S subjects</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Treatment group</bold>
</th></tr><tr valign="top"><th>
<bold>System Organ Class (SOC) preferred term</bold>
</th><th>
<bold>Diclegis (N&#x02009;=&#x02009;131)</bold>
</th><th>
<bold>Placebo (N&#x02009;=&#x02009;127)</bold>
</th><th>
<bold>P-value</bold>
<sup><bold>1</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td># of Subjects with at least one TEAE</td><td>74 (56.5%)</td><td>65 (51.2%)</td><td>0.39</td></tr><tr valign="top"><td>Cardiac disorders</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Palpitations</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Eye disorders</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Dry eye</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Gastrointestinal disorders</td><td>23 (17.6%)</td><td>22 (17.3%)</td><td>0.960</td></tr><tr valign="top"><td>Constipation</td><td>2 (1.5%)</td><td>2 (1.6%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Dry mouth</td><td>4 (3.1%)</td><td>1 (0.8%)</td><td>0.370<sup>2</sup>
</td></tr><tr valign="top"><td>Haematemesis</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Feeling jittery</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>
<bold>Laboratory Investigations</bold>
</td><td>7 (5.3%)</td><td>6 (4.7%)</td><td>0.820</td></tr><tr valign="top"><td>Alanine aminotransferase increased</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Aspartate aminotransferase increased</td><td>0</td><td/><td/></tr><tr valign="top"><td>Blood albumin decreased</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Blood amylase increased</td><td>2 (1.5%)</td><td>2 (1.6%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Blood chloride decreased</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Blood creatinine increased</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Blood lactate dehydrogenase increased</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Blood sodium decreased</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Blood triglycerides increased</td><td/><td>1 (0.8%)</td><td>0</td></tr><tr valign="top"><td>Gamma-glutamyltransferase increased</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Heart rate increased</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Platelet count decreased</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>
<bold>Nervous system disorders</bold>
</td><td>42 (32.1%)</td><td>37 (29.1%)</td><td>0.610</td></tr><tr valign="top"><td>Dizziness</td><td>8 (6.1%)</td><td>8 (6.3%)</td><td>0.949</td></tr><tr valign="top"><td>Headache</td><td>17 (13.0%)</td><td>20 (15.7%)</td><td>0.526</td></tr><tr valign="top"><td>Loss of consciousness</td><td>0</td><td>1 (0.8%)</td><td>0.492<sup>2</sup>
</td></tr><tr valign="top"><td>Poor quality sleep</td><td>1 (0.8%)</td><td>0</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Somnolence</td><td>19 (14.5%)</td><td>15 (11.8%)</td><td>0.523</td></tr><tr valign="top"><td>Syncope</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1.000<sup>2</sup>
</td></tr><tr valign="top"><td>Fatigue</td><td>9 (6.9%)</td><td>8 (6.3%)</td><td>0.853</td></tr></tbody></table><table-wrap-foot><p>
<sup>1</sup>The p-value for comparing Treatment groups uses Chi-square test method.</p><p>
<sup>2</sup>P-value is calculated using Fisher&#x02019;s exact test method.</p><p>At each level of summarization (SOC/preferred term), subjects reporting more than one AE will only be counted once.</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Most frequently occurring Treatment Emergent Adverse Events (TEAEs) in the study for ITT-S subjects</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="3">
<bold>Treatment group</bold>
</th></tr><tr valign="top"><th>
<bold>System Organ Class (SOC) preferred term</bold>
</th><th>
<bold>Diclegis (N&#x02009;=&#x02009;131)</bold>
</th><th>
<bold>Placebo (N&#x02009;=&#x02009;127)</bold>
</th><th>
<bold>P-value</bold>
<sup><bold>1</bold></sup>
</th></tr></thead><tbody><tr valign="top"><td># of Subjects with at least one TEAE</td><td>74 (56.5%)</td><td>65 (51.2%)</td><td>0.393</td></tr><tr valign="top"><td>Gastrointestinal disorders</td><td>23 (17.6%)</td><td>22 (17.3%)</td><td>0.960</td></tr><tr valign="top"><td>Abdominal pain</td><td>5 (3.8%)</td><td>8 (6.3%)</td><td>0.362</td></tr><tr valign="top"><td>General disorders and administration site</td><td>13 (9.9%)</td><td>12 (9.4%)</td><td>0.897</td></tr><tr valign="top"><td>Conditions</td><td/><td/><td/></tr><tr valign="top"><td>Fatigue</td><td>9 (6.9%)</td><td>8 (6.3%)</td><td>0.949</td></tr><tr valign="top"><td>Musculoskeletal and connective tissue</td><td>11 (8.4%)</td><td>4 (3.1%)</td><td>0.072</td></tr><tr valign="top"><td>Disorders</td><td/><td/><td/></tr><tr valign="top"><td>Back pain</td><td>7 (5.3%)</td><td>4 (3.1%)</td><td>0.383</td></tr><tr valign="top"><td>Nervous system disorders</td><td>42 (32.1%)</td><td>37 (29.1%)</td><td>0.610</td></tr><tr valign="top"><td>Dizziness</td><td>8 (6.1%)</td><td>8 (6.3%)</td><td>0.949</td></tr><tr valign="top"><td>Headache</td><td>17 (13.0%)</td><td>20 (15.7%)</td><td>0.526</td></tr><tr valign="top"><td>Somnolence</td><td>19 (14.5%)</td><td>15 (11.8%)</td><td>0.523</td></tr></tbody></table><table-wrap-foot><p>
<sup>1</sup>The p-value for comparing Treatment groups uses Chi-square test method.</p><p>TEAEs that are considered most frequently occurring include the events (in preferred terms) reported by at least 5% of subjects in any of the treatment groups.</p><p>At each level of summarization (SOC/preferred term), subjects reporting more than one AE will only be counted once.</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Treatment Emergent Adverse Events (TEAEs) with respect to relationship to study drug- related vs. unrelated for ITT-S subjects</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="4">
<bold>Treatment group</bold>
</th></tr><tr valign="top"><th/><th colspan="2">
<bold>Diclegis (N&#x02009;=&#x02009;131)</bold>
</th><th colspan="2">
<bold>Placebo (N&#x02009;=&#x02009;127)</bold>
</th></tr><tr valign="top"><th>
<bold>System Organ Class (SOC) preferred term</bold>
</th><th>
<bold>Related</bold>
</th><th>
<bold>Unrelated</bold>
</th><th>
<bold>Related</bold>
</th><th>
<bold>Unrelated</bold>
</th></tr></thead><tbody><tr valign="top"><td># of Subjects with at least one</td><td>40 (30.5%)</td><td>34 (26.0%)</td><td>32 (25.2%)</td><td>33 (26.0%)</td></tr><tr valign="top"><td>TEAE in the study</td><td/><td/><td/><td/></tr><tr valign="top"><td>Cardiac disorders</td><td>1 (0.8%)</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Palpitations</td><td>1 (0.8%)</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Eye disorders</td><td>0</td><td>1 (0.8%)</td><td>0</td><td>0</td></tr><tr valign="top"><td>Dry eye</td><td>0</td><td>1 (0.8%)</td><td>0</td><td>0</td></tr><tr valign="top"><td>Gastrointestinal disorders</td><td>8 (6.1%)</td><td>15 (11.5%)</td><td>8 (6.3%)</td><td>14 (11.0%)</td></tr><tr valign="top"><td>Abdominal pain</td><td>1 (0.8%)</td><td>4 (3.1%)</td><td>3 (2.4%)</td><td>5 (3.9%)</td></tr><tr valign="top"><td>Abdominal pain upper</td><td>0</td><td>3 (2.3%)</td><td>2 (1.6%)</td><td>3 (2.4%)</td></tr><tr valign="top"><td>Constipation</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1 (0.8%)</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Diarrhea</td><td>2 (1.5%)</td><td>2 (1.5%)</td><td>1 (0.8%)</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Dry mouth</td><td>4 (3.1%)</td><td>0</td><td>1 (0.8%)</td><td>0</td></tr><tr valign="top"><td>Dyspepsia</td><td>1 (0.8%)</td><td>4 (3.1%)</td><td>1 (0.8%)</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Flatulence</td><td>0</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Salivary hypersecretion</td><td>0</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>General disorders and administration</td><td>7 (5.3%)</td><td>6 (4.6%)</td><td>6 (4.7%)</td><td>6 (4.7%)</td></tr><tr valign="top"><td>Feeling jittery</td><td>1 (0.8%)</td><td>0</td><td>0</td><td>0</td></tr><tr valign="top"><td>Nervous system disorders</td><td>33 (25.2%)</td><td>9 (6.9%)</td><td>24 (18.9%)</td><td>13 (10.2%)</td></tr><tr valign="top"><td>Dizziness</td><td>6 (4.6%)</td><td>2 (1.5%)</td><td>5 (3.9%)</td><td>3 (2.4%)</td></tr><tr valign="top"><td>Headache</td><td>8 (6.1%)</td><td>9 (6.9%)</td><td>8 (6.3%)</td><td>12 (9.4%)</td></tr><tr valign="top"><td>Loss of consciousness</td><td>0</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Poor quality sleep</td><td>0</td><td>1 (0.8%)</td><td>0</td><td>0</td></tr><tr valign="top"><td>Somnolence</td><td>19 (14.5%)</td><td>0</td><td>15 (11.8%)</td><td>0</td></tr><tr valign="top"><td>Syncope</td><td>1 (0.8%)</td><td>0</td><td>0</td><td>1 (0.8%)</td></tr><tr valign="top"><td>Fatigue</td><td>6 (4.6%)</td><td>3 (2.3%)</td><td>5 (3.9%)</td><td>3 (2.4%)</td></tr></tbody></table><table-wrap-foot><p>Related category includes Possible, Probable, and Definite relationships. Unrelated category includes unlikely and not related.</p><p>At each level of summarization (SOC/preferred term), subjects reporting more than on AE will only be counted once under the strongest relationship.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The randomized trial described herein has previously shown the superiority of Diclegis&#x000ae; over placebo in treating the symptoms of NVP in American women managed in 3 academic centers [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>In Canada, the doxylamine succinate-pyridoxine hydrochloride combination (Diclectin&#x000ae;) has been available since 1979 [<xref ref-type="bibr" rid="CR17">17</xref>], with a large number of studies corroborating the initial FDA evaluation of its efficacy and safety [<xref ref-type="bibr" rid="CR18">18</xref>-<xref ref-type="bibr" rid="CR20">20</xref>]. The present study had a placebo arm, as symptoms of NVP tend to subside spontaneously in most women by the end of the first trimester [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition, when considering maternal safety associated with the first trimester of pregnancy, symptoms such as fatigue, tendency to sleep and dehydration, may be erroneously attributed to the drug, rather than to both pregnancy and NVP.</p><p>The use of Diclegis&#x000ae; was not associated with an increased risk of any adverse effects when compared to placebo, lending important reassurance to its use by large numbers of pregnant women.</p><p>It may be puzzling, however, how symptoms of CNS depression, so typical of the sedating antihistamines, were more prevalent in the active arm of the study. The answer may lie in the demographics of the study population as presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p>The mean weight of the women in the study was 75&#x000a0;kg (165&#x000a0;lb), rendering 24% of them overweight and 42% obese. When the original Bendectin&#x000ae; studies were conducted the mean weight of participating women was 20&#x000a0;kg lower on average. As a result we might hypothesize that the relatively lower weight-adjusted dose given to our mostly overweight and obese study participants could have mitigated adverse drug effects.</p><p>A previous study determined the incidence of adverse maternal effects among 225 women taking Diclectin&#x000ae; at the recommended (n&#x02009;=&#x02009;123) or higher than recommended (n&#x02009;=&#x02009;102) doses [<xref ref-type="bibr" rid="CR21">21</xref>]. One-third (33.6%) of those women reported having adverse CNS effects (sleepiness, tiredness, and/or drowsiness) temporally related to the medication, a rate very similar to the present study (28.3%). In that study there was no association between the dose per kg and rates of reported maternal adverse effects with doses ranging from 0.1&#x000a0;mg/kg to 2.0&#x000a0;mg/kg (1&#x02013;12 tablets). In addition, the higher than standard dose of Diclectin&#x000ae;, when calculated per kg of body weight, did not affect either the incidence or severity of maternal adverse effects. Similarly, no excess was recorded for other typical adverse effects of antihistamine, such as those involved in low gastrointestinal motility or anticholinergic effects (e.g. dry mouth, dysrhythmia).</p><p>In a recent population- based Canadian study, pregnant women in the first trimester of pregnancy, when NVP and the use of Diclegis&#x000ae; is at its peak, did not have a higher risk of car crushes, whereas there was a 46% increased risk in the second trimester, when most morning sickness has subsided and the drug is not used [<xref ref-type="bibr" rid="CR21">21</xref>]. This may serve as a population-based corroboration of the present results, showing that Diclegis&#x000ae; is not associated with measurable CNS depression.</p></sec><sec id="Sec5" sec-type="conclusion"><title>Conclusions</title><p>Based on this secondary analysis of results from a double blind placebo controlled trial, the pyridoxine-doxylamine combination appears to be safe to the pregnant woman suffering from NVP.</p><p>CTR No. NCT006 14445, 2007.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>GK has served as a paid consultant of Duchesnay Inc. The study was sponsored by Duchesnay Inc., Blainville, Quebec.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>GK: designed the study, analyzed and wrote the first draft. SC, GDV, SNC, JGU, MM: recruited and managed patients and participated in interpretation and writing. DRM: participated in interpretation and writing. IM: Analyzed the data, participated in interpretation and writing. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Special thanks to all nurses and clinical staff involved in this study.</p><p>The study was supported by Duchesnay Inc., Blainville, Quebec, Canada and executed by Premier Research Group, Philadelphia, PA.</p><p>The opinions expressed in this manuscript are those of the authors and do not necessarily reflect the policy or opinion of NICHD, NIH or HHS.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Bishai</surname><given-names>R</given-names></name></person-group><source>Nausea and Vomiting of Pregnancy: State of the art, 2000</source><year>2000</year><publisher-loc>Toronto</publisher-loc><publisher-name>The Motherisk Program</publisher-name><fpage>5</fpage><lpage>9</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arsenault</surname><given-names>MY</given-names></name><name><surname>Lane</surname><given-names>CA</given-names></name><name><surname>MacKinnon</surname><given-names>CJ</given-names></name><name><surname>Bartellas</surname><given-names>E</given-names></name><name><surname>Cargill</surname><given-names>YM</given-names></name><name><surname>Klein</surname><given-names>MC</given-names></name><etal/></person-group><article-title>SOGC clinical practice guidelines: the management of nausea and vomiting of pregnancy</article-title><source>J Obstet Gynaecol Can</source><year>2002</year><volume>24</volume><issue>10</issue><fpage>817</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12405123</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Pastuszak</surname><given-names>A</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name></person-group><article-title>Drugs in pregnancy</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1128</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1056/NEJM199804163381607</pub-id><pub-id pub-id-type="pmid">9545362</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Food and Drug administration U.S</collab></person-group><source>Department of Health and Human Services, Public Health Services, Talk Paper</source><year>1983</year></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Federal Register /Vol. 64, No 152/August 9, 1999/Notes, Determination that Bendectin was not withdrawn from sale for reasons of safety or effectiveness.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neutel</surname><given-names>CI</given-names></name><name><surname>Johansen</surname><given-names>HL</given-names></name></person-group><article-title>Measuring drug effectiveness by default: the case of Bendectin</article-title><source>Can J Public Health</source><year>1995</year><volume>86</volume><issue>1</issue><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">7728721</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutcher</surname><given-names>JS</given-names></name><name><surname>Engle</surname><given-names>A</given-names></name><name><surname>Firth</surname><given-names>J</given-names></name><name><surname>Lamm</surname><given-names>SH</given-names></name></person-group><article-title>Bendectin and birth defects. II: ecological analyses</article-title><source>Birth Defects Res A Clin Mol Teratol</source><year>2003</year><volume>67</volume><issue>2</issue><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/bdra.10034</pub-id><pub-id pub-id-type="pmid">12769503</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeigue</surname><given-names>PM</given-names></name><name><surname>Lamm</surname><given-names>SH</given-names></name><name><surname>Linn</surname><given-names>S</given-names></name><name><surname>Kutcher</surname><given-names>JS</given-names></name></person-group><article-title>Bendectin and birth defects: I. A metaanalysis of the epidemiologic studies</article-title><source>Teratology</source><year>1994</year><volume>50</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/tera.1420500105</pub-id><pub-id pub-id-type="pmid">7974252</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einarson</surname><given-names>TR</given-names></name><name><surname>Leeder</surname><given-names>JS</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>A method for meta-analysis of epidemiological studies</article-title><source>Drug Intell Clin Pharm</source><year>1988</year><volume>22</volume><issue>10</issue><fpage>813</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">3229352</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Diclectin&#x000ae;</collab></person-group><source>Product Monograph</source><year>2008</year><publisher-loc>Blainville Quebec, Canada</publisher-loc><publisher-name>Duchesnay Inc</publisher-name></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nulman</surname><given-names>I</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclectin&#x000ae;) and oral solutions of these drugs in healthy women of childbearing age</article-title><source>Can J Clin Pharmacol</source><year>2009</year><volume>16</volume><issue>3</issue><fpage>e400</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19923636</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Caritis</surname><given-names>SN</given-names></name><name><surname>Miodovnik</surname><given-names>M</given-names></name><name><surname>Umans</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial</article-title><source>Am J Obstet Gynecol</source><year>2010</year><volume>203</volume><issue>6</issue><fpage>571</fpage><pub-id pub-id-type="doi">10.1016/j.ajog.2010.07.030</pub-id><pub-id pub-id-type="pmid">20843504</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Boskovic</surname><given-names>R</given-names></name><name><surname>Hard</surname><given-names>M</given-names></name><name><surname>Maltepe</surname><given-names>C</given-names></name><name><surname>Navioz</surname><given-names>Y</given-names></name><name><surname>Einarson</surname><given-names>A</given-names></name></person-group><article-title>Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2002</year><volume>186</volume><issue>5</issue><fpage>S228</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1067/mob.2002.123054</pub-id><pub-id pub-id-type="pmid">12011891</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Piwko</surname><given-names>C</given-names></name><name><surname>Ahn</surname><given-names>E</given-names></name><name><surname>Boskovic</surname><given-names>R</given-names></name><name><surname>Maltepe</surname><given-names>C</given-names></name><name><surname>Einarson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores</article-title><source>J Obstet Gynaecol</source><year>2005</year><volume>25</volume><issue>3</issue><fpage>241</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1080/01443610500060651</pub-id><pub-id pub-id-type="pmid">16147725</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname><given-names>N</given-names></name><name><surname>Maltepe</surname><given-names>C</given-names></name><name><surname>Garcia-Bournissen</surname><given-names>F</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Nausea and vomiting of pregnancy: using the 24-hour pregnancy-unique quantification of emesis (PUQE-24) scale</article-title><source>J Obstet Gynecol Can</source><year>2009</year><volume>31</volume><fpage>803</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19941704</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The American College of Obstetricians and Gynecologists</collab></person-group><article-title>Nausea and vomiting of pregnancy</article-title><source>ACOG Practice Bulletin No 52</source><year>2004</year><volume>103</volume><issue>4</issue><fpage>803</fpage><lpage>15</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornstein</surname><given-names>M</given-names></name><name><surname>Einarson</surname><given-names>A</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Bendectin/diclectin for morning sickness: a Canadian follow-up of an American tragedy</article-title><source>Reprod Toxicol</source><year>1995</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0890-6238(94)00050-7</pub-id><pub-id pub-id-type="pmid">8520127</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boskovic</surname><given-names>R</given-names></name><name><surname>Einarson</surname><given-names>A</given-names></name><name><surname>Maltepe</surname><given-names>C</given-names></name><name><surname>Wolpin</surname><given-names>J</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing</article-title><source>J Obstet Gynaecol Can</source><year>2003</year><volume>25</volume><issue>10</issue><fpage>830</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">14532951</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atanackovic</surname><given-names>G</given-names></name><name><surname>Navioz</surname><given-names>Y</given-names></name><name><surname>Moretti</surname><given-names>ME</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>The safety of higher than standard dose of doxylamine succinate-pyridoxine hydrochloride (Diclectin) for nausea and vomiting of pregnancy</article-title><source>J Clin Pharmacol</source><year>2001</year><volume>41</volume><issue>8</issue><fpage>842</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1177/00912700122010735</pub-id><pub-id pub-id-type="pmid">11504271</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nulman</surname><given-names>I</given-names></name><name><surname>Rovet</surname><given-names>J</given-names></name><name><surname>Barrera</surname><given-names>M</given-names></name><name><surname>Knittel-Keren</surname><given-names>D</given-names></name><name><surname>Feldman</surname><given-names>BM</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin</article-title><source>J Pediatr</source><year>2009</year><volume>155</volume><issue>1</issue><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2009.02.005</pub-id><pub-id pub-id-type="pmid">19394042</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Redelmeie DAR, May SC, Thiruchelvam D, Barrett JF. Pregnancy and the risk of a traffic crash. CMAJ May 12, 2014 doi:10.1503/cmaj.131650.</mixed-citation></ref></ref-list></back></article>